Insider Selling: Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $38,556.60 in Stock

Zai Lab Limited (NASDAQ:ZLAB) CFO Yajing Chen sold 2,154 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $17.90, for a total transaction of $38,556.60. Following the transaction, the chief financial officer now owns 13,714 shares of the company’s stock, valued at approximately $245,480.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Yajing Chen also recently made the following trade(s):

• On Thursday, April 4th, Yajing Chen sold 845 shares of Zai Lab stock. The stock was sold at an average price of $15.67, for a total transaction of $13,241.15.
• On Tuesday, April 2nd, Yajing Chen sold 519 shares of Zai Lab stock. The shares were sold at an average price of $16.15, for a total transaction of $8,381.85.

Zai Lab Stock Down 1.1 %

ZLAB opened at $17.33 on Friday. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $32.60. The firm’s fifty day simple moving average is $18.36 and its 200 day simple moving average is $20.14.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.38. The company had revenue of $87.15 million for the quarter, compared to analyst estimates of $77.07 million. Zai Lab had a negative return on equity of 40.21% and a negative net margin of 116.45%. During the same period in the previous year, the company posted ($0.51) earnings per share. On average, research analysts predict that Zai Lab Limited will post -2.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a report on Tuesday, June 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $64.57.

Hedge Funds Weigh In On Zai Lab

A number of large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in shares of Zai Lab by 1,923.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,550 shares of the company’s stock worth $70,000 after purchasing an additional 2,424 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Zai Lab by 51.2% in the 1st quarter. BNP Paribas Financial Markets now owns 2,671 shares of the company’s stock valued at $43,000 after buying an additional 904 shares during the last quarter. Headlands Technologies LLC bought a new stake in Zai Lab during the 1st quarter worth about $64,000. Sectoral Asset Management Inc. boosted its stake in shares of Zai Lab by 33.3% during the 4th quarter. Sectoral Asset Management Inc. now owns 4,000 shares of the company’s stock worth $109,000 after buying an additional 1,000 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Zai Lab in the 4th quarter valued at about $116,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.